Soleno Therapeutics (SLNO) Other Non-Current Assets (2015 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Other Non-Current Assets of $163000.0 for Q1 2026, up 96.39% year-over-year from $83000.0 in Q1 2025, and little changed quarter-over-quarter from $163000.0 in Q4 2025.
Soleno Therapeutics (SLNO) Other Non-Current Assets (2015 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Other Non-Current Assets for 12 consecutive years, with $163000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 96.39% year-over-year to $163000.0; the TTM figure through Mar 2026 stood at $163000.0 (up 96.39% YoY), while the FY2025 annual figure was $163000.0, up 96.39% from the prior year.
- Other Non-Current Assets was little changed at $163000.0 in Q1 2026 per SLNO's latest filing, from $163000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $165000.0 in Q2 2023 and bottomed at $40000.0 in Q1 2022.
- Historically, Other Non-Current Assets has averaged $117857.1 across 5 years, with a median of $104500.0 in 2023.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets surged 215.0% — and 2024, when it sank 49.7%.
- Soleno Therapeutics' Other Non-Current Assets stood at $40000.0 in 2022, then soared by 312.5% to $165000.0 in 2023, then tumbled by 49.7% to $83000.0 in 2024, then jumped by 96.39% to $163000.0 in 2025, then changed by 0.0% to $163000.0 in 2026.
- Business Quant data shows SLNO's Other Non-Current Assets at $163000.0 in Q1 2026, $163000.0 in Q4 2025, and $83000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 163,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 163,000.00 |
| Dec 31, 2025 | 163,000.00 |
| Sep 30, 2025 | 83,000.00 |
| Jun 30, 2025 | 83,000.00 |
| Mar 31, 2025 | 83,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Jun 30, 2024 | 83,000.00 |
| Mar 31, 2024 | 165,000.00 |
| Dec 31, 2023 | 165,000.00 |
| Sep 30, 2023 | 165,000.00 |
| Jun 30, 2023 | 165,000.00 |
| Mar 31, 2023 | 126,000.00 |
| Mar 31, 2022 | 40,000.00 |
| Dec 31, 2021 | 40,000.00 |
| Sep 30, 2021 | 40,000.00 |
| Jun 30, 2021 | 40,000.00 |
| Dec 31, 2020 | 15,000.00 |
| Mar 31, 2020 | 59,000.00 |
| Dec 31, 2019 | 59,000.00 |